Delivers consistent absorption14
Bypasses problems associated with the GI tract14
Allows for on-demand use. See dosing information
Increase in mean plasma levels within 5 minutes
Median Tmax compared with
120 minutes for oral CD/LD‡
*4 to 5 hours after morning CD/LD, patients ate a meal and then received study drug.
†INBRIJA 84 mg coadministered with 25 mg oral carbidopa for true PK comparison to levodopa.
‡Median Tmax represented to account more accurately for outliers.
SD, standard deviation; Tmax, time to peak drug concentration.
INBRIJA is indicated for intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD) treated with carbidopa/levodopa.
Please see the Full Prescribing Information.
Intermittent treatment of OFF episodes in patients with PD treated with CD/LD.
Contraindicated in patients taking or who have recently taken (within 2 weeks) nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine) due to hypertension risk. Discontinue use of nonselective MAO inhibitors at least 2 weeks prior to initiating INBRIJA.